Table 2.
Comparison of immune cells according to various factors in patients with colitis-associated cancer.
| Disease | CD (n = 8) | UC (n = 16) | p-value |
|---|---|---|---|
| CD3, mm2, mean (SD) | 371 (205) | 358 (185) | 0.818 |
| CD8, mm2, mean (SD) | 166 (101) | 306 (194) | 0.153 |
| Foxp3, mm2, mean (SD) | 64 (67) | 92 (63) | 0.214 |
| PD-L1, mm2, mean (SD) | 304 (319) | 168 (182) | 0.192 |
| Age | <43.3 (n = 14) | ≥43.3 (n = 10) | p-value |
| CD3, mm2, mean (SD) | 415 (172) | 289 (192) | 0.105 |
| CD8, mm2, mean (SD) | 282 (195) | 228 (160) | 0.476 |
| Foxp3, mm2, mean (SD) | 77 (69) | 90 (60) | 0.633 |
| PD-L1, mm2, mean (SD) | 274 (273) | 130 (156) | 0.148 |
| Location of tumor | Left colon (n = 20) | Right colon (n = 4) | p-value |
| CD3, mm2, mean (SD) | 337 (189) | 490 (126) | 0.157 |
| CD8, mm2, mean (SD) | 249 (176) | 312 (215) | 0.525 |
| Foxp3, mm2, mean (SD) | 80 (61) | 96 (87) | 0.794 |
| PD-L1, mm2, mean (SD) | 223 (260) | 169 (72) | 0.525 |
| CEA | <5 (n = 18) | ≥5 (n = 6) | p-value |
| CD3, mm2, mean (SD) | 357 (179) | 379 (229) | 0.820 |
| CD8, mm2, mean (SD) | 273 (183) | 219 (178) | 0.537 |
| Foxp3, mm2, mean (SD) | 82 (62) | 85 (77) | 0.923 |
| PD-L1, mm2, mean (SD) | 220 (258) | 195 (186) | 0.974 |
| Stage | Stage I–III (n = 16) | Stage IV (n = 8) | p-value |
| CD3, mm2, mean (SD) | 436 (170) | 214 (124) | 0.007 |
| CD8, mm2, mean (SD) | 339 (160) | 100 (89) | <0.001 |
| Foxp3, mm2, mean (SD) | 105 (64) | 37 (32) | 0.007 |
| PD-L1, mm2, mean (SD) | 189 (172) | 263 (345) | 0.487 |
| Disease activity | Mild (n = 13) | Moderate to severe (n = 11) | p-value |
| CD3, mm2, mean (SD) | 342 (196) | 385 (183) | 0.733 |
| CD8, mm2, mean (SD) | 277 (184) | 239 (181) | 0.733 |
| Foxp3, mm2, mean (SD) | 95 (54) | 69 (75) | 0.093 |
| PD-L1, mm2, mean (SD) | 136 (102) | 306 (318) | 0.167 |
| Steroids | Use (n = 3) | No use (n = 21) | p-value |
| CD3, mm2, mean (SD) | 434 (229) | 352 (185) | 0.401 |
| CD8, mm2, mean (SD) | 347 (206) | 247 (178) | 0.354 |
| Foxp3, mm2, mean (SD) | 166 (86) | 71 (53) | 0.052 |
| PD-L1, mm2, mean (SD) | 118 (89) | 227 (251) | 0.561 |
| Immunosuppressive agents | Use (n = 8) | No use (n = 16) | p-value |
| CD3, mm2, mean (SD) | 345 (200) | 371 (187) | 0.881 |
| CD8, mm2, mean (SD) | 184 (133) | 297 (191) | 0.264 |
| Foxp3, mm2, mean (SD) | 71 (69) | 89 (63) | 0.528 |
| PD-L1, mm2, mean (SD) | 296 (325) | 172 (180) | 0.320 |
| Anti-TNF agents | Use (n = 3) | No use (n = 21) | p-value |
| CD3, mm2, mean (SD) | 191 (64) | 387 (187) | 0.101 |
| CD8, mm2, mean (SD) | 64 (48) | 287 (174) | 0.023 |
| Foxp3, mm2, mean (SD) | 22 (15) | 91 (64) | 0.041 |
| PD-L1, mm2, mean (SD) | 557 (440) | 165 (161) | 0.082 |
| Lymphovascular invasion | Positive (n = 8) | Negative (n = 11) | p-value |
| CD3, mm2, mean (SD) | 385 (182) | 415 (199) | 0.657 |
| CD8, mm2, mean (SD) | 328 (185) | 288 (174) | 0.717 |
| Foxp3, mm2, mean (SD) | 99 (64) | 90 (70) | 0.717 |
| PD-L1, mm2, mean (SD) | 193 (232) | 253 (266) | 0.442 |
| MSI status | MSI-high (n = 3) | MSS (n = 16) | p-value |
| CD3, mm2, mean (SD) | 435 (180) | 396 (194) | 0.875 |
| CD8, mm2, mean (SD) | 379 (196) | 291 (173) | 0.359 |
| Foxp3, mm2, mean (SD) | 88 (13) | 95 (72) | 0.712 |
| PD-L1, mm2, mean (SD) | 153 (18) | 242 (269) | 1.000 |
CD, Crohn’s disease; UC, ulcerative colitis; MSI, microsatellite instability; MSS, microsatellite stable.